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Current biopharmaceutical manufacturing systems are not compatible with portable or
distributed production of biologics, as they typically require the development of single
biologic-producing cell lines followed by their cultivation at very large scales. Therefore, it
remains challenging to treat patients in short time frames, especially in remote locations with
limited infrastructure. To overcome these barriers, we developed a platform using genetically
engineered Pichia pastoris strains designed to secrete multiple proteins on programmable cues
in an integrated, benchtop, millilitre-scale microﬂuidic device. We use this platform for rapid
and switchable production of two biologics from a single yeast strain as speciﬁed by the
operator. Our results demonstrate selectable and near-single-dose production of these
biologics ino24 h with limited infrastructure requirements. We envision that combining this
system with analytical, puriﬁcation and polishing technologies could lead to a small-scale,
portable and fully integrated personal biomanufacturing platform that could advance disease
treatment at point-of-care.
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iopharmaceutical production is one of the largest con-
tributors to escalating expenditures in healthcare, in
particular due to the length, complexity and high costs
associated with product discovery and development as well as the
cost of construction and scale-up of biomanufacturing1–3. In
addition, biologics treatment of patients in remote parts of the
world, battleﬁelds, emergency situations or under-developed
regions with poor infrastructure presents formidable logistical
challenges that greatly impact drug availability at the point-of-
care4–9.
Currently, manufacturing of biologic drugs in the bio-
pharmaceutical industry relies heavily on large-scale fermentation
batches that are frequently monitored ofﬂine, to ensure a robust
process and consistent quality of product4,8,10. However, as
personalized medicines, single-use technologies and the desire for
global and decentralized access to biologics are becoming
increasingly important, there is a growing need for rapid,
ﬂexible, scalable and portable biomanufacturing systems that
can be monitored/controlled online for affordable, safe and
consistent production of biologics11.
To address this demand for personalized biomanufacturing
technologies, we developed a new platform for ﬂexible and
portable production of biologic therapeutics at the point-of-care
in short time frames and with limited system requirements. The
basic components of this platform are as follows: (1) a biologics
expression system engineered to secrete multiple therapeutic
proteins in response to programmable cues and (2) an integrated,
small overall footprint, millilitre-scale perfusion microﬂuidic
platform capable of supporting rapid and ﬂexible biomanufactur-
ing process control that enables portable operations in mobile
units, such as vehicles (Fig. 1 and Supplementary Movie 1).
We demonstrate that this system produces near-single-dose
levels of recombinant human growth hormone (rHGH) and
interferon-a2b (IFNa2b) in o24 h.
Results
Host selection. Recombinant biologics for therapeutic use in
humans can be produced using a variety of host organisms,
including bacteria, yeast, plants, insect cells and mammalian
cells12. The speciﬁc host used can have an impact on yields, need
for viral inactivation, downstream puriﬁcation requirements, as
well as ﬁnal product formulation. Mammalian Chinese Hamster
Ovary (CHO) cells are the most commonly used host for
producing Food and Drug Administration (FDA)-approved
biologics9, but they have complex media requirements and their
storage requires cryopreservation. Therefore, the long time
needed to go from inoculation of biologic-producing CHO cells
to release of a drug product, which meets established quality
standards and an FDA-approved safety proﬁle, is incompatible
with a rapid production system. Yeast are attractive alternatives to
CHO cells, as they have simple media requirements, grow quickly
to high densities and can be stored as lyophilized material12,13.
Pichia pastoris (also known as Komagataella phafﬁ) is becoming
increasingly popular for biologic production, as it (1) can grow to
very high densities on simple and inexpensive carbon sources; (2)
has a strong yet tightly controlled alcohol oxidase 1 (AOX1)
promoter, which can be induced by methanol for high level
protein production (up to 10 g l 1) and is effectively repressed by
glycerol or glucose; (3) is capable of human-like posttranslational
modiﬁcations, including glycosylation14–16; and (4) secretes
heterologous proteins into the extracellular space very efﬁciently
with minimal host protein contamination, thus requiring
relatively simple downstream puriﬁcation systems17,18.
To date, more than 500 different proteins, including simple
peptides, enzymes, hormones, monoclonal antibodies and
FDA-approved therapeutics have been expressed in P. pastoris1,4,5.
Thus, as a proof-of-concept of ﬂexible biologics manufacturing using
a single host, we developed strains of P. pastoris to support the
independently selectable production of two different therapeutics.
The use of individual strains that support production of multiple
biologics provides signiﬁcant advantages over the use of multiple
strains that each produce single biologics. First, leveraging strains
that produce multiple biologics for rapid production of dosage-level
biologics enables the re-use of accumulated biomass from the
outgrowth period. This approach dramatically improves production
speed by avoiding the need to regrow different strains into
production-level biomass. Second, for production of multi-
component products, the FDA requires approval of multiple
manufacturing lines that each produce individual components and
thus a single multiplexed expression platform could offer a potential
regulatory advantage.
The AOX1 promoter (PAOX1) is useful for producing one protein
on-demand. Only a few alternative inducible promoters have been
characterized in P. pastoris, including the CUP1, G1 or FLD1
promoters. However, it remains unclear whether these promoters
support high levels of expression, while remaining orthogonal to
PAOX1 (refs 19–21). Thus, to enable selectable bioproduction, we
sought to develop new inducible promoters that are orthogonal to
and can surpass PAOX1 in promoter strength.
Transformation platform. Current transformation methods for
P. pastoris rely on genomic integration of small linearized
plasmids through homologous recombination, followed by anti-
biotic selection and screening for high-copy-number integrants22.
Although these approaches are adequate for simple genetic
manipulations, such as introducing small expression cassettes,
they have several limitations for more sophisticated synthetic
biology applications. In addition, multiple random integration
events are undesirable when attempting to compare expression
levels between different genetic constructs.
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Figure 1 | Point-of-care biomanufacturing by integrating genetically
engineered strains and portable microbioreactors for programmable
biologics expression. P. pastoris strains genetically engineered to contain
independently controllable inducible genetic cassettes were used within
portable perfusion microbioreactors to achieve high-density and
programmable expression of two biologic drugs. Here we show the
microbioreactor system in the context of an ambulance.
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To accelerate the rapid design-test-and-optimize cycle for
creating new promoters, we ﬁrst sought to overcome the rate-
limiting step of plasmid transformation and genomic integration
of synthetic constructs into P. pastoris. We created a recombi-
nase-based system for the single-copy integration of plasmids at
deﬁned loci that is suitable even for large DNA constructs
(Fig. 2a). We ﬁrst generated a parent P. pastoris strain containing
attB sites for the recombinases BxbI, R4 and TP-901 (ref. 23).
This was accomplished by traditional integration of a construct
containing regions of homology to the Trp2 locus in the
P. pastoris genome (Supplementary Tables 1 and 2, Integration
Site 1), attB sites and a KanR selection cassette. Integration at the
Trp2 locus was validated using PCR and a copy number of 1 was
veriﬁed using quantitative PCR (qPCR; Supplementary Fig. 1).
We then co-transformed a plasmid for the transient expression of
BxbI, R4 or TP901, together with a transfer plasmid containing
attP sites for the corresponding recombinase and engineered
genetic constructs of interest. This method typically generated
B50–300 transformants per reaction for DNA constructs ranging
from B7.8 to 13.6 kb (Supplementary Fig. 2).
Optimization of b-estradiol-inducible expression systems.
Using this integration strategy, we implemented an inducible
transcriptional system consisting of a constitutively expressed
zinc-ﬁnger (ZF) DNA-binding domain24 fused with the
b-estradiol binding domain of the human oestrogen receptor,
which is coupled with a transcriptional activation domain25.
At steady state, this synthetic ZF transcription factor (ZF-TF) is
sequestered in the cytoplasm by HSP90. Addition of b-estradiol
displaces HSP90 and permits translocation of the ZF-TF into the
nucleus, where it activates expression of genes regulated by a
minimal promoter placed downstream of multiple ZF-binding
sites (Fig. 2b). This system offers a highly ﬂexible architecture that
can be tuned by modifying different parameters, including the
following: (1) afﬁnity of the DNA-binding domain to DNA; (2)
strength of the transcriptional activation domain; (3) number of
binding sites for the ZF; (4) promoter driving expression of the
ZF; (5) minimal promoter driving expression of the output; (6)
dose of inducer; and (7) integration site.
Initial tuning of expression levels was performed with green
ﬂuorescent protein (GFP) as the output quantiﬁed using ﬂow
cytometry. The ZF DNA-binding domain used in these experi-
ments was ZF43-8 (ref. 24). We fused the ZF DNA-binding
domain and b-estradiol-binding domain of the human oestrogen
receptor to the VP64 transcriptional activation domain, which
has been previously shown to mediate higher levels of expression
in mammalian cells than other domains, such as p65 or VP16
(ref. 26). The Saccharomyces cerevisiae TEF1 promoter was used
to express the ZF-TF and a minimal GAP promoter preceded by
nine binding sites for ZF43-8 was used to drive the inducible
expression of GFP. At 24 h, dose–response curves showed that
maximum expression of GFP could be attained with only 0.01 mM
b-estradiol (Fig. 2c). However, at 48 h, 0.1–1 mM b-estradiol was
necessary to fully saturate this system.
We further optimized gene expression by modulating the
number and placement of ZF-binding sites within the artiﬁcial
promoter, which have been shown to be important parameters
for maximizing the expression of regulated genes27. We used a
ppTEF1 promoter to express the ZF-TF, which targeted a
minimal CYC promoter preceded by single ZF-binding sites
placed B200, B350 orB500 upstream of the ATG start codon,
as well as combinations of two or three ZF-binding sites. We also
tested one promoter with nine binding sites spaced B20 bp and
one promoter with nine ZF-binding sites spaced B40 bp from
each other (with the closest ZF-binding site located 200 bp
upstream of the ATG codon of the output gene). We found that
promoters with nine binding sites expressed GFP at higher levels
than promoters with three binding sites when induced, whereas
increasing the spacing between binding sites did not signiﬁcantly
improve levels of expression (Fig. 3).
Chromosomal context is an important factor to consider when
expressing heterologous genes, because promoter interference,
chromatin structure or other epigenetic modiﬁcations can have a
negative impact on gene activation28,29. Thus, we tested
GFP expression from cassettes integrated at nine different
chromosomal loci. These loci correspond to regions targeted in
prior reports22,30 or to intergenic regions, to avoid directly
disrupting native coding sequences (Supplementary Tables 1
and 2). We did not observe statistically signiﬁcant differences in
the maximally induced levels of gene expression across nine loci
(Supplementary Fig. 3).
The performance of the ZF-inducible expression system can be
further affected by two additional parameters: the strength of the
promoter driving expression of the ZF-TF and the basal activity
of the minimal promoter, which contains ZF-binding sites, that
controls expression of the output. The promoter driving ZF-TF
expression is constitutive and determines how much ZF-TF
accumulates in the cytoplasm. Excessive ZF-TF levels can
potentially surpass the capacity of HSP90 to sequester the
ZF-TF in the cytoplasm and, as a result, the ZF-TF may
spontaneously translocate into the nucleus and activate expres-
sion in the absence of inducer, thus increasing undesired
background. To minimize background expression levels, the
minimal promoter containing ZF-binding sites should activate
gene expression only when the inducer is present.
To ﬁne-tune the expression of our output signal, we expressed
the ZF-TF from several constitutive promoters previously used in
P. pastoris, as well as variations of the GAP promoter that we
constructed by introducing B50 bp insertions throughout its
DNA sequence to modify its activity (Supplementary Fig. 4).
We built combinations of these ZF-TF-expressing constitutive
promoters with minimal promoters derived from those that
regulate AOX1, GAP, a GAP6 variant, GCW14 and S. cerevisiae
CYC1 (Fig. 4). We measured GFP expression via ﬂow cytometry
with and without induction with b-estradiol. The different
combinations exhibited a wide range of background expression
levels and maximal activation ratios (Fig. 4a). Interestingly, some
of the combinations consistently supported maximum expression
levels higher than those reached by GFP expressed directly from
the well-characterized PAOX1 under maximal induction
(Supplementary Fig. 5). Overall, combinations that exhibited
higher maximum expression levels also had greater background
levels in the OFF state.
We selected three architectures that had ON/OFF ratios in
excess of B4-fold and/or high maximal expression activities for
further engineering (architectures 245, 246 and 255; Fig. 4b). We
then added an expression cassette to produce red ﬂuorescent
protein (RFP) using the AOX1 promoter to these vectors and
generated strains 245R, 246R and 255R, respectively (Fig. 5a).
As expected, these strains expressed GFP when induced with
b-estradiol in buffered glycerol-complex medium (BMGY),
expressed RFP when induced with buffered methanol-complex
medium (BMMY) and expressed both GFP and RFP when
induced with b-estradiol in BMMY (Fig. 5b).
Using the synthetic expression cassettes that were optimized
with intracellular ﬂuorescent reporters 245R, 246R and 255R
(Fig. 5b), we then built a proof-of-concept system to controllably
produce two biologic drugs, rHGH and IFNa2b. This resulted in
three strains capable of selectable expression of two different
biologics: strain 245B (GAP promoter expressing ZF-TF,
AOX1 minimal promoter with ZF-binding sites expressing rHGH
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and AOX1 promoter expressing IFNa2b), strain 246B (GAP6
promoter expressing ZF-TF, AOX1 minimal promoter with
ZF-binding sites expressing rHGH and AOX1 promoter expres-
sing IFNa2b) and strain 255B (scTEF1 promoter expressing
ZF-TF, GAP minimal promoter with ZF-binding sites expressing
rHGH and AOX1 promoter expressing IFNa2b). Strain 245B,
246B and 255B were capable of selectable production of
high-dose rHGH or IFNa2b in shake ﬂasks within 24 h of
induction (Fig. 5c).
Interestingly, the level of protein secretion was similar from
the AOX1 promoter or the b-estradiol-inducible system when
rHGH expression was induced after 48 h of outgrowth
(Supplementary Fig. 6). One difference between the systems is
that b-estradiol can be used to induce protein secretion without
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Figure 2 | Development of artiﬁcial promoter systems for high-level transgene expression in P. pastoris. (a) Schematic representation of the
landing-pad-based integration system used in these studies. We ﬁrst generated a parental strain containing landing pads based on attB sites for the
recombinases BxbI, R4 and TP-901.1. This strain can be efﬁciently transformed with a transfer vector containing the desired gene circuit and the
corresponding attP site together with a plasmid encoding the corresponding recombinase. (b) Schematic representation of the b-estradiol-inducible system
used for in this study. This system uses a ZF DNA-binding domain fused to the b-estradiol-binding domain of the human oestrogen receptor, which is
coupled to a transcriptional activation domain. This synthetic ZF-TF is sequestered in the cytoplasm by HSP90. Addition of b-estradiol displaces HSP90
and permits translocation of the ZF-TF into the nucleus, where it activates expression of genes regulated by a minimal promoter placed downstream of
multiple ZF-binding sites. (c) Dose–response and time course of GFP expression using the b-estradiol-inducible system, where the S. cerevisiae TEF1
promoter was used to express the ZF-TF, and a minimal GAP promoter preceded by nine binding sites of ZF43-8 was used for inducible expression of GFP.
b-Estradiol (0.1–1mM) is necessary to achieve full activation of this system at 48 h. Error bars represent s.e.m. (n¼ 3).
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outgrowth, while using glycerol as a carbon source, thereby
allowing growth and production to occur simultaneously.
Methanol induction, however, requires biomass accumulation
(typically in glycerol) before the induction phase22. Without prior
biomass accumulation, protein production from AOX1 was
signiﬁcantly lower than production from a b-estradiol-inducible
promoter (Supplementary Fig. 7). As the daily dose of rHGH
needed to treat patients is higher than the dose of IFNa2b,
we engineered P. pastoris strains for expression of rHGH on
b-estradiol stimulation and expression of IFNa2b on methanol
stimulation. To maximize protein production, we further tested
different media additives and determined that formulations
containing the antifoams L81, P2000 and AF204 enhanced
rHGH secretion levels from strain 255, where GFP was replaced
with rHGH (Supplementary Fig. 8).
Continuous and selectable protein production in micro-
bioreactors. Sequential manufacturing of multiple biological
therapeutics from individual strains requires rapid changes to
their environment in high-density cell cultures. Furthermore,
manufacturing at the volume scale of individual doses
(for example, millilitres) suits requirements for point-of-care
applications. For example, a production yield of 120 mgml 1 for
IFNa2b in yeast31 could result in multiple doses when produced
at the millilitre scale, as a common formulation of IFNa2b
(Intron-A, db00105) is 11.6 mg (ref. 32). These two requirements
can be complementary as the large surface-area-to-volume ratio
afforded by miniature systems facilitates rapid media changeover.
To demonstrate this, we developed a protocol speciﬁcally tailored
for programmable protein production with our engineered strains
in an integrated, millilitre-scale table-top microbioreactor that
can be operated continuously for point-of-care use in personal
biomanufacturing, even with limited resources. By combining our
engineered dual-biologics strain with the operational ﬂexibility of
the microbioreactor device, we extended the traditional
biomanufacturing approach, where a single biologic is produced
per process, into one that enables sequential or controllable
expression of multiple different biologics.
The principal component of the microbioreactor is a
polycarbonate-Polydimethylsiloxane (PDMS) membrane-poly-
carbonate sandwiched chip with active microﬂuidic circuits
outﬁtted pneumatically for routing of reagents, precise peristaltic
injection, growth chamber mixing and ﬂuid extraction (Fig. 6a)33.
We used an injection volume of 700B900 nl per injection for
precise control of ﬂuid addition/extraction in the 1-ml volume
growth chamber. A 0.8-mm pore size perfusion ﬁlter
(polyethersulfone) with a 1-cm diameter was incorporated
underneath the growth chamber, to allow for ﬂuid ﬂow-through
while maintaining all of the cells inside the growth chamber and
enabling the switching of induction media (Fig. 6a). The ratio of
the ﬁlter surface area to bioreactor volume was 0.758—a factor of
3 higher than high-performance, bench-scale perfusion
bioreactors previously reported34.
To demonstrate the paradigm of personalized, single-dose
and programmable biomanufacturing, we performed 3-day
continuous cultivation experiments for selectable production of
two biologics at near-single-dose levels in o24 h. The dual-
biologics-producing P. pastoris strain 255B was inoculated from a
single colony and grown in BMGY, ﬁrst in batch and then in
perfusion mode, with a perfusion rate of 0.5ml h 1. At 24 h, the
outgrowth media was switched to our custom methanol media
with perfusion rates of 1ml h 1 for 4 h for rapid changeover of
the chemical environment, followed by IFNa2b collection at a
perfusion rate of 0.5ml h 1 for 20 h. The 1ml h 1 changeover
rate was chosen to ensure that 498% of the preceding medium
had been ﬂushed out after this 4-h medium changeover period
according to our rate equation model for microbioreactor
operation (see ‘Microbioreactor ﬂow modelling’ in Methods).
After the 48-h time point, we switched the custom methanol
media with the custom b-estradiol-containing media at a
perfusion rate of 1ml h 1 for 4 h, followed by a collection phase
for rHGH lasting 20 h at a perfusion rate of 0.5ml h 1.
A summary of the microbioreactor control operation is provided
in Table 1. The different operational phases are illustrated with
the online optical density (OD) plot in Fig. 6b. This experimental
procedure resulted in 10ml of perfusate for each protein
production period lasting 20 h each.
During the cultivation, cells inside the growth chamber were
rapidly circulated and mixed by peristalsis. The fermentation
temperature was controlled at 30±0.1 C. The online OD was
recorded through an optical path length of B250 mm by a
630-nm light-emitting diode, where the optical path length is
chosen to maximize the linear response range compatible with
our fabrication process. The dissolved oxygen level of the culture
was monitored online and controlled by dynamically changing
the gas feed line between air and oxygen to match the dissolved
oxygen set point, which was set to 100% air saturation in the
experiment. The online pH data were also recorded during the
fermentation process. The real-time sensor data for the micro-
bioreactor experiments presented here can be found in the
Supplementary Fig. 9. A video showing the peristaltic mixing and
optical sensing in the microbioreactor during the culture is
provided in Supplementary Movie 2. We used four different input
ports for the injection of BMGY outgrowth media, custom-made
methanol media for IFNa2b production, b-estradiol-containing
media for rHGH production and water for evaporation
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compensation. Perfusate was collected through the ﬂuid channel
downstream of the perfusion ﬁlter for protein characterization.
For portable storage operation where lyophilized material may be
used, the lyophilized material can be re-suspended in the
reconstitution media before inoculation. This can serve as the
seed inoculum and be injected into the growth chamber during
the inoculation process. The cells could be revived inside the
growth chamber subsequently without the need of additional
steps. If the reconstitution media differs from the outgrowth
media, a perfusion media changeover to the outgrowth media can
be performed after the revival process.
To understand induction dynamics and protein secretion
levels, we collected samples every hour during the 4-h media
switching periods. In addition, during the 20-h production
periods, we ﬁrst collected four samples every 2.5 h and then one
sample after the last 10 h. A standard enzyme-linked immuno-
sorbent assay (ELISA) was carried out to quantify protein
production. As shown in Fig. 6c, production proﬁles for the two
biologics corresponded to the different induction media toggled
by the microbioreactor. Four parallel microbioreactor experi-
ments were carried out at the same time with identical protocols.
Induction with methanol resulted in the rapid secretion of
IFNa2b, which reached maximal productivity after only 3 h and
remained constant during the production period, and then
rapidly decreased after methanol was removed from the media.
Similarly, rHGH secretion was induced via media changeover to
the custom b-estradiol-containing media, thus demonstrating
multi-product expression control in our integrated platform.
A summary of cumulative protein production and measure-
ments of wet cell weight at the end of the experiment averaged
across the four microbioreactors is shown in Table 2. The total
average production of IFNa2b was 19.73 mg per reactor, which
exceeds the 11.6 mg dose in Intron-A, whereas the total average
production of rHGH was 43.7 mg per reactor (a common starting
weight-based formulation of rHGH (Nutropin) is 0.006mg kg 1
per day35). Therefore, even without extensive bioprocess
optimization, this system is capable of producing IFNa2b in
excess of the daily dose needed in adults and matching the daily
dose rHGH required to treat infants. Importantly, the cultivation
conditions in the perfusion microbioreactor provided continuous
nutrient supplies and high oxygen transfer rates33 that led to the
highest reported cell culture density achieved in any microﬂuidic
platform, measured as an average wet cell weight of
356±27 g l 1 (ref. 36). In addition to the microbioreactor run
shown in Fig. 6, three additional microbioreactor runs operating
the same protocol were carried out. The additional results are
shown in Supplementary Fig. 10.
Discussion
The choice of therapeutic molecules and the regulatory gene
circuits used in a multiplexed biomanufacturing platform is
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important. For example, our current expression systems can
achieve B110-fold and B4-fold ON:OFF ratios for IFNa2b and
rHGH, respectively. However, concerns about background
production of biologic A during induction of biologic B and vice
versa could make downstream puriﬁcation processes and
the regulatory approval process more challenging. Using
recombinase-based switches to invert protein-expressing DNA
cassettes37,38 or additional repressors could reduce leakage
beyond the transcriptional systems used here. For example,
biologics-expressing cassettes could be surrounded by
recombinase-recognition sites and initially encoded in inactive
positions; expression of a recombinase could invert a targeted
cassette and allow an upstream promoter to transcribe the correct
messenger RNA. In addition, translational repressors or RNA
interference could be used to further knock down undesirable
expression levels in uninduced conditions. Combinatorial
assembly of large numbers of genetic circuits followed by high-
throughput screening for ones with enhanced ON:OFF ratios
could further lower background expression. The integration of
puriﬁcation platforms with our biomanufacturing system could
also help reduce background levels of biologics in uninduced
states. To circumvent the limited number of inducible systems
available for controlling biologics expression, future work could
integrate more advanced gene circuits, such as multiplexers that
enable a restricted set of n inputs to control the expression of 2n
outputs. Additional inducible systems that leverage orthogonal
chemical inputs or non-chemical inputs, such as light, could
further help with the scalability of this system and, in the latter
case, reduce logistics requirements.
Producing multi-component products such as vaccines
could also circumvent the issue of undesirable background
production, as multiple products could be expressed from a single
strain. Furthermore, synthetic biology could help tailor a vaccine
for speciﬁc populations, as different antigens are likely to be
optimal in providing immunity depending on geographical
location or timing. With artiﬁcial regulation over the expression
of different antigens, we could control the ultimate formulation of
multi-component vaccines on demand for optimal prophylaxis
and mitigate concerns about background expression. These
vaccines could be customized to speciﬁc outbreaks or local
conditions to enhance their applicability. Currently, the
production of such multi-component vaccines can require
multiple manufacturing lines, each with its own FDA approval.
A multiplexed expression platform for multi-component vaccines
could conceivably reduce the regulatory burden for such products.
Similarly, the controlled expression of multi-component biologic
products could also beneﬁt from this approach and help mitigate
concerns over leaky background expression.
By combining genetic and hardware engineering, we have
demonstrated a proof-of-concept, integrated and highly ﬂexible
platform for the programmable production of two biopharma-
ceuticals, IFNa2b and rHGH. Future work includes scaling up the
number of products that can be controllably manufactured,
selecting speciﬁc drug candidates that are compatible with each
other, enhancing production levels while reducing background
expression levels and integrating this system with puriﬁcation,
polishing and analytics39. We envision that such technologies will
enable the creation of small-scale, portable, fully integrated and
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Figure 5 | Selectable biologics production from P. pastoris strains with both an estradiol-inducible circuit and a methanol-inducible circuit. (a) Three
strains containing circuit architectures with acceptable ON/OFF ratios were selected (245, 246 and 255) and added an RFP expression cassette controlled
by the methanol-inducible AOX1 promoter (245R, 246R and 255R). (b) These strains expressed GFP when induced with b-estradiol in BMGY, expressed
RFP when induced with BMMY and expressed both GFP and RFP when induced with b-estradiol in BMMY for 24 h. Error bars represent s.e.m. (n¼ 3).
(c) Strains 245B, 246B and 255B were generated by replacing GFP and RFP in strains 245R, 246R and 255R with rHGH and IFNa2b. Protein gel
electrophoresis and Coomassie staining of supernatants from shake ﬂasks demonstrated high-level expression of the desired biologic drug on stimulation
for 24 h in BMGY for b-estradiol or BMMY for methanol.
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closed biomanufacturing systems that can advance the treatment
of human diseases at the point-of-care.
Methods
Different media formulations namely BMGY, yeast extract peptone dextrose
(YPD), BMMY, custom-made methanol medium and b-estradiol-containing salt
medium were used in these experiments. BMGY medium contained 10 g l 1
(1% (w/v)) yeast extract (VWR catalogue #90004-092), 20 g l 1 (2% (w/v)) peptone
(VWR catalogue #90000-264), 100mM potassium phosphate monobasic (VWR
catalog #MK710012), 100mM potassium phosphate dibasic (VWR catalog #97061-
588), 4 10 5% biotin (Life Technologies #B1595), 13.4 g l 1 (1.34% (w/v)) Yeast
Nitrogen Base (Sunrise Science catalogue #1501-500) and 2% glycerol (VWR
catalogue #AA36646-K7). YPD contained 1% yeast extract, 2% peptone and 2%
dextrose (VWR catalogue # BDH0230). BMMY contained 1% yeast extract, 2%
peptone, 100mM potassium phosphate monobasic, 100mM potassium phosphate
dibasic, 4 10 5% biotin and 10ml l 1 (1% (v/v)) methanol (VWR catalogue
#VWRCBDH20864.4). The custom-made methanol medium contained 1.34%
Yeast Nitrogen Base, 0.79 g l 1 casaminoacids (Fisher #BP1424-500), 2% methanol
(VWR catalogue #VWRCBDH20864.4) and 0.1% antifoam 204 (Sigma-Aldrich
catalogue #A8311-50ML). The b-estradiol-containing salt medium contained
30 mM b-estradiol (Sigma-Aldrich catalogue #E4389-100MG), 18.2 g l 1 K2SO4
(VWR catalogue #97062-578), 7.28 g l 1 MgSO4 (Sigma-Aldrich catalogue
#M7506-500G), 4.3 g l 1 KOH (Fisher #P250-1), 0.08 g l 1 CaSO4 2H2O (Sigma
Aldrich catalogue #C3771-500G), 13ml l 1 85% orthophosphoric acid (VWR
catalogue #E582-50ML), 1.47 g l 1 sodium citrate (Fisher #S279-500), 0.1%
antifoam 204 and pH adjusted to 5.5 with ammonium hydroxide (Sigma-Aldrich
catalogue #318612-500ML). All individual reagents were prepared as stock
solutions and mixed immediately before the experiments. BMGY, custom-made
methanol medium and b-estradiol-containing salt medium were used in the
experiment for initial outgrowth, IFNa2b production and rHGH production,
respectively.
Plasmid construction. The multiple constructs used in these experiments were
built using conventional restriction enzyme cloning and/or Gibson assembly using
the vector pPICZ A (Invitrogen #V190-20) as the backbone. All plasmids used in
this manuscript are described in Supplementary Table 3 and have been deposited
in the Addgene plasmid repository.
Strains. The wild-type Pichia pastoris strain NRRL Y- 11430, ATCC 76273
(reclassiﬁed as Komagataella phafﬁi) was used in this study.
Electroporation. Competent cells were prepared by ﬁrst growing one single colony
of P. pastoris in 5ml YPD at 30 C overnight. Fifty microlitres of the resulting
culture were inoculated in 100ml of YPD and grown at 30 C overnight again to an
OD600 B1.3–1.5. The cells were then centrifuged at 1,500 g for 5min at 4 C and
resuspended with 40ml of ice-cold sterile water, centrifuged at 1,500 g for 5min at
4 C and resuspended with 20ml of ice-cold sterile water, centrifuged at 1,500 g for
5min at 4 C and resuspended in 20ml of ice-cold 1M sorbitol, and centrifuged at
1,500 g for 5min at 4 C and resuspended in 0.5ml of ice-cold 1M sorbitol. For
transformation of the landing pad plasmids, 80 ml of competent cells were mixed
with 5–20 mg of linearized DNA and transferred to an ice-cold 0.2 cm electro-
poration cuvette for 5min. For recombinase-based transformations, 10 mg of
circular transfer vector and 10 mg of circular recombinase expression vector were
combined, added to 80ml of competent cells and incubated for 5min in an ice-cold
0.2 cm electroporation cuvette. Pulse parameters were 1,500V, 200O and
25 mF. Immediately after pulsing, 1ml of ice-cold 1M sorbitol was added to the
cuvette and the cuvette content was transferred to a sterile culture tube containing
2 YPD. The culture tubes were incubated for 2 h at 30 C with shaking
and 50–100 ml of the culture was spread on Yeast Extract Peptone Dextrose
Sorbitol (YPDS) plates (1% yeast extract, 2% peptone, 1M sorbitol, 1% dextrose
and 2% agar) with the appropriate selection antibiotic (zeocin 100 mgml 1;
G418 100 mgml 1).
Cell induction and ﬂow cytometry. One single colony was grown in 1ml of
BMGY in a 12-ml culture tube at 30 C in a shaking incubator (250–300 r.p.m.)
overnight. The cells were centrifuged at 500 g for 5min at room temperature and
washed twice with PBS. After the second wash, the cells were resuspended in
induction medium consisting of BMMY or BMGY with b-estradiol. After 24 h, the
cultures were centrifuged at 500 g for 5min at room temperature, washed with 1ml
of PBS twice, resuspended in 1ml of PBS and used for ﬂow cytometry with a LSR
Fortessa cell analyser.
ELISA assay. The concentration of hGH and IFN-a2b in each of the samples
was determined by ELISA assay. Solid-phase 96-well ELISA plates were used,
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Figure 6 | Programmable protein production in a millilitre-scale table-top
microbioreactor. (a) The principal component of the microbioreactor is a
polycarbonate-PDMS membrane-polycarbonate sandwiched chip with
active microﬂuidic circuits that are equipped for pneumatic routing of
reagents, precise peristaltic injection, growth chamber mixing and ﬂuid
extraction. (b) Three-day continuous cultivation experiments for selectable
production of two biologics were performed. The different operational
phases are colour coded in the online OD plot for one experiment. The
microbioreactor enabled high-density cell cultures up to a wet-cell weight
(WCW) of 356±27 g l 1. (c) Samples were collected at the indicated time
points and protein production was measured using ELISA, which
demonstrated near single-dose drug production levels in fewer than 24 h.
Error bars represent s.e.m. (n¼4).
Table 1 | Microbioreactor operation.
Time Medium Flow rate Purpose
0h BMGY 0 Outgrowth
14–24 h BMGY 0.5ml h 1 Outgrowth
24–28 h Methanol medium 1.0ml h 1 Rapid medium switchover
28–48 h Methanol medium 0.5ml h 1 IFNa2b production
48–52 h b-Estradiol medium 1.0ml h 1 Rapid medium switchover
52–72 h b-Estradiol medium 0.5ml h 1 rHGH production
BMGY, buffered glycerol-complex medium; IFNa2b, interferon-a2b; rHGH, recombinant human
growth hormone.
Summary table including the microbioreactor operation timeline, inﬂow medium, ﬂow rate and
purpose for different operation phases in Fig. 6b.
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speciﬁcally designed for the quantiﬁcation of hGH (Quantikine ELISA, R&D
Systems) and IFN-a (Verikine Human IFN-alpha ELISA Kit, PBL Assay Science).
The products were provided with the proper standard stock solutions or
powder for each of the assays. For hGH, the standard curve was calculated using
concentrations ranging between 3,200 and 25 rgml 1, in twofold serial dilutions.
For IFNa2b, the extended range standard curve was used, with an additional large
concentration point: the standard concentration varied between 156 and
10,000 rgml 1, in twofold serial dilutions. For both assays, negative controls were
also included. Before the protein quantiﬁcation, the samples were diluted in the
appropriate buffer so that the concentrations determined would fall within the
assay and equipment limits.
The optical density values obtained for each of the assays were plotted using a
four-parameter ﬁt for the standard curve. Each sample was measured twice and the
results represent the average and s.d. of three biological replicates.
Quantitative PCR. Genomic DNA from different strains was isolated using the
YeaStar Genomic DNA kit (Zymo) and the resulting preps were diluted down to a
concentration of 5 ng ml 1. qPCR mixtures were prepared using the LightCycler
480 SYBR Green Master mix (Roche) with 10 ng genomic DNA from each strain
was used with 400 nM of each primer per assay in a total reaction volume of 20 ml.
Reactions were performed in LightCycler 480 96-well reaction plates in triplicate
with a standard curve for each gene generated from serial ten-fold dilutions of 2 ng
of plasmid DNA containing the gene-of-interest. The ampliﬁcation conditions were
as follows: 95 C for 10min followed by 45 cycles of 95 C for 10 s, 56 C for 15 s
and 72 C for 20 s. The ampliﬁcation period was followed by a melting curve
analysis with a temperature gradient of 0.1 C s 1 from 65 C to 95 C. An
amplicon from the single-copy GAPDH or ACT1 genes was used for normalization.
Using the published genome size of 9.4Mbp, we expected 98,000 copies of the
genome to be present in 1 ng haploid P. pastoris genomic DNA. Absolute copy
number for the gene-of-interest in each strain was calculated using the mean Ct
value and the corresponding standard curve.
The sequence of the primers used were as follows: hGH (50-GGGCAGATCTT
CAAGCAGAC-30 , 50-CTCGACCTTGTCCATGTCCT-30); IFN (50-TTCCCACA
AGAGGAATTTGG-30 , 50-AGGCTGCTGAGGAATCTTTG-30); GAPDH (50-TGG
GTTACACTGAAGATGCC-30, 50-CGTTGTCGTACCAAGAGATCAG-30); ACT1
(50-TGGTATCGTTTTGGACTCTGG-30 , 50-AGCGTGTGGTAAGGAGAAAC-30);
and landing pad (50-TGTCTTCGTGGTTTGTCTGG-30, 50-TCTTGTAGTTGCC
GTGTCG-30).
Microbioreactor. Parts for the microbioreactor experiment were purchased
from Pharyx Inc. A single bioreactor control hub (Pharyx, #MBS-004) with an
overall footprint of 31 cm (w) 34 cm (d) 36 cm (h) was used to control four
independent microbioreactor units (Pharyx, #MCM-001) for the fermentation
experiment. Each microbioreactor unit interfaces with a single-use disposable
microﬂuidic chip made of a sandwiched polycarbonate-PDMS membrane-
polycarbonate structure (Pharyx, #CCPST-1) to carry out peristaltic control
and online sensing. The design, fabrication and system conﬁguration for the
microbioreactor have been described previously33,40. To provide the rapid medium
changeover required for this study, a perfusion ﬁlter (Pall Corp., Supor 800,
#60109) was incorporated into the cultivation chamber41 to allow medium
ﬂow-through, while maintaining cells inside the growth chamber.
Microbioreactor ﬂow modelling. To account for the microbioreactor media
concentration dynamics during the changeover period, a simple model based
on ﬂuid concentration rate equation under equal inﬂow and outﬂow rate was
constructed. For simplicity, cellular consumption on media material was not taken
into account in this model. Assuming that S (t) represents a particular medium
concentration in the growth chamber, Sin (t) represents the concentration of this
medium in the input ﬂow, F represents the input ﬂow rate and V represents the
growth chamber volume, then the rate equation for the medium concentration in
the growth chamber can be modelled as
@SðtÞ
@t
¼ F
V
Sin tð Þ S tð Þ½ :
For the situation of introducing a completely new medium into the growth
chamber to replace an old medium similar to our programmable biologics
production experiment, assuming Sin (t) is constant during the time of changeover
and t¼ 0 being the start of changeover event, the new medium concentration can
be simply solved analytically as
Snew tð Þ ¼ Sinð1 e FVtÞ:
Meanwhile, the concentration of the old medium due to ﬂush out follows as
Sold tð Þ ¼ Solde FVt ;
assuming Sold is the concentration of the old medium before the changeover event.
Therefore, a ﬂow rate of 1ml h 1 for the changeover period of 4 h would result in
a medium replacement percentage of B1 e 4E98.2%. In contrast, if the
changeover rate stays as 0.5ml h 1 similar to the case for the production period,
the medium replacement percentage would be B1 e 2E86.5%, where there
would still be a substantial amount of the previous medium leftover after the
changeover event. Such physical modelling of the microbioreactor operation
provides a simple yet effective design guideline to complement the operational
ﬂexibility of our manufacturing platform.
Microbioreactor experiment. The microbioreactor chips were g-irradiated and
sealed as part of the standard pre-inoculation sterile protocol. The medium bottles
and feed lines were autoclaved separately. The initial inoculum was loaded from a
single colony from a YPD plate stored at 4 C at 0 h. The fermentation parameter
plot for the online OD, dissolved oxygen, pH and temperature for one experiment
is shown in Supplementary Fig. 9. As described in the manuscript, the fermentation
temperature was controlled at 30±0.1 C throughout the entire experiment. The
dissolved oxygen level of the microbioreactor was controlled by dynamically
changing the gas feed line between air and oxygen to match the dissolved oxygen
set point, which was set to 100% air saturation in the experiment. As the cells grow
and the overall oxygen consumption rate increases, the gas controller gradually
increases the oxygen content in the gas feed line to maintain the dissolved oxygen
set point. Once the cell oxygen consumption rate overpasses the oxygen transfer
rate by pure oxygen supply, the dissolved oxygen drops below the set point and the
supply gas remains at 100% oxygen. The online OD is monitored through light
scattering across an optical path length of B250 mm inside the growth chamber
with a 630-nm light-emitting diode. The linear response range for this OD sensor is
around 0B0.7 online OD unit. AboveB0.7 online OD unit, the sensor reading no
longer increases linearly with the cell density. The online pH data are also recorded
during the fermentation process. The pH sensor is rated for pH values of 5.5B8.5.
During the third day, the pH reading falls below 5.5 and therefore may not
accurately represent the actual pH of the culture environment. Over the course of
the study, perfusate samples were collected downstream of the perfusion ﬁlter and
were stored at 4 C before processing with ELISA assay.
Additional microbioreactor runs. In addition to the microbioreactor run
presented in the body manuscript, three additional runs of the microbioreactor
experiments were performed over the course of 5 months. Each run is marked by
the time of the experiment and consists of two independent microbioreactors
operating the same protocol in parallel. The protein concentration time course plot
is shown in Supplementary Fig. 10 and the cumulative protein production quantity
is summarized in Supplementary Table 4. Overall, the same switching behaviour
was observed across all runs with some run-to-run protein production variations
observed, especially for the December 2014 Run, where rHGH production was
much higher than the rest. These run-to-run variations are probably caused by our
experimentation with the inner surface coating and g-irradiation protocol of the
microbioreactor chip. After the microbioreactor parts were fabricated and bonded,
an inner surface coating protocol with polyethylene glycol (PEG)-silane treatment
was carried out, followed by a chip nitrogen purge and bagging procedure, and
g-irradiation sterilization. Some experimentation on this protocol in terms of
PEG-silane treatment time and chip nitrogen purge procedure in search for the
optimal coating condition was carried across the early microbioreactor runs. For all
runs, the chips used in the same run were fabricated with exactly the same protocol
and therefore do not cause much variation within each microbioreactor run. As we
standardized our chip fabrication protocol during this 5-month time period, our
run-to-run variations reduced substantially (the March 2015 Run and the main
body run that happened in June 2015 had much less production variations com-
pared with the rest). Nonetheless, the result from the March 2015 Run suggests the
potential of high production yield comparable to industrial level for our
Table 2 | Microbioreactor production.
IFNa2b rHGH IFNa2b rHGH Wet cell weight
Production (20 h) Production (20 h) Leakage (20h) Leakage (20h)
19.73±0.72mg 43.7±6.3mg 0.177±0.032mg 10.8±2.9 mg 356±27 g l 1
IFNa2b, interferon-a2b; rHGH, recombinant human growth hormone.
Production summary for IFNa2b and rHGH, and wet cell weight measurement at the end of the experiment. All data are averaged across four independent microbioreactors running the same protocol in
parallel. Values represent mean and s.e.m. (n¼4).
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manufacturing platform with suitable manufacturing standardization and biopro-
cess optimization.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon request. The plasmids used in this manuscript
have been deposited in Addgene. Addgene accession numbers can be found in
Supplementary Table 3.
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